89bio Inc

89bio — Investor Presentation (December 2023)

69 slides from 89bio's investor presentation, Dec 6, 2023

  1. Slide 1: Powerful Science Meaningful Medicines Changing Lives

    Exhibit 99.1 Powerful Science Meaningful Medicines Changing Lives Nasdaq: ETNB December 2023

  2. Slide 2: Disclaimers

    Disclaimers This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in

  3. Slide 3: Corporate Highlights

    Corporate Highlights Potential Best-in-Class FGF21 in Two Phase 3 programs, each of which * represents a significant market opportunity Nonalcoholic Steatohepatitis (NASH) Program 1 • Strongest fibrosis data in category with favorable tolerability and dosing convenience • First FGF21 with positive 4

  4. Slide 4: Advancing Pegozafermin in Clinical Development

    Advancing Pegozafermin in Clinical Development INDICATION TRIAL PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NASH Phase 3 trial in F2/F3: Histology & Outcomes – 1Q24 Breakthrough Therapy designation Phase 3 trial in F4: Histology & Outcomes – 2Q24 Phase 3 trial – Ongoing SHTG 3

  5. Slide 5: Pegozafermin Data Published in Prestigious Journals

    Pegozafermin Data Published in Prestigious Journals 4

  6. Slide 6: Pegozafermin is an FGF21 Analog Optimally Engineered

    Pegozafermin is an FGF21 Analog Optimally Engineered to Balance Efficacy and Long Dosing Interval glycoPEG(20kD) FGF21 Pegozafermin EC (nM) EC (nM) 50 50 Strong and flexible linker RECEPTOR Mean ± S.D. Mean ± S.D. (glycoPEGylation technology) Position 182 KLB nd nd KLB/FGFR1 4.5 ± 1.0 0.3 ± 0.07 N-t

  7. Slide 7: Opportunity in NASH

    Opportunity in NASH

  8. Slide 8: Pegozafermin Offers Potential Best-in-Class Therapeutic for NASH

    * Pegozafermin Offers Potential Best-in-Class Therapeutic for NASH REDUCES LIVER FAT FAVORABLE TOLERABILITY & IMPROVES REVERSES LIVER FIBROSIS RESOLVES NASH CONVENIENT DOSING INSULIN to improve patient RESISTANCE persistence and compliance IMPROVES DYSLIPIDEMIA * If approved 7

  9. Slide 9: ENLIVEN Trial Evaluated QW and Q2W Dosing in NASH F2-F3

    ENLIVEN Trial Evaluated Weekly (QW) and Every-Two-Week (Q2W) Dosing in Patients with NASH F2-F3 BLINDED PRIMARY ENDPOINTS MAIN STUDY EXTENSION PHASE (24 weeks) (24 weeks) • ≥1-stage fibrosis improvement 1 with no worsening of NASH Placebo (QW or Q2W) PLACEB PLO* ACEBO (QWQ2 orW Q2W) • NASH resolutio

  10. Slide 10: Baseline Characteristics Well Balanced Across Dose Groups

    Baseline Characteristics Well Balanced Across Dose Groups Parameter Placebo 15mg QW 30mg QW 44mg Q2W Total Mean or % (n=71) (n=21) (n=73) (n=57) (n=222) Age (years) 56 55 55 55 56 Female 55% 43% 69% 65% 61% 2 BMI (kg/m ) 38 38 35 36 37 Type 2 Diabetes 69% 86% 62% 61% 66% Fibrosis Stage (% F3) 66% 43

  11. Slide 11: Statistical Significance on Fibrosis Improvement

    WEEK 24 Pegozafermin Demonstrated Statistical Significance on Fibrosis Improvement at 30mg QW and 44mg Q2W Dose Fibrosis Improvement Without Worsening of NASH at Week 24 p=0.008 40% p=0.008 p=0.1 30% 27% 26% 22% 20% 19% 20% 15% 10% 7% 0% Placebo 15mg QW 30mg QW 44mg Q2W n=61 n=14 n=66 n=51 * Relativ

  12. Slide 12: Comparative Clinical Data in Non-Cirrhotic Patients: Fibrosis

    Comparative Clinical Data in Non-Cirrhotic Patients ≥1 Stage Fibrosis Improvement with No Worsening of NASH (placebo-adjusted) ƚ 2 Pegozafermin Ocaliva Resmetirom Lanifibranor Semaglutide Efruxifermin Phase 3 | 52 weeks Phase 2b | 24 weeks Phase 3 | 72 weeks Phase 2b | 24 weeks Phase 2 | 72 weeks Ph

  13. Slide 13: Statistical Significance on NASH Resolution at All Doses

    WEEK 24 Pegozafermin Demonstrated Statistical Significance on NASH Resolution at All Doses NASH Resolution Without Worsening of Fibrosis at Week 24 p=0.0005 p=0.0009 50% p<0.0001 40% 37% 30% 26% 23% 20% 35% 24% 21% 10% 2% 0% Placebo 15mg QW 30mg QW 44mg Q2W n=61 n=14 n=66 n=51 * Relative Risk 1.0 18

  14. Slide 14: Comparative Clinical Data: NASH Resolution

    Comparative Clinical Data in Non-Cirrhotic Patients NASH Resolution with No Worsening of Fibrosis ƚ 2 Pegozafermin Ocalivia Resmetirom Lanifibranor Semaglutide Efruxifermin Phase 2b | 24 weeks Phase 3 | 72 weeks Phase 3 | 52 weeks Phase 2b | 24 weeks Phase 2 | 72 weeks Phase 2b | 24 weeks 1 Multiple

  15. Slide 15: Combined Endpoint of Fibrosis Improvement and NASH Resolution

    WEEK 24 Pegozafermin Demonstrated Statistical Significance on the Combined Endpoint of Fibrosis Improvement and NASH Resolution Both Fibrosis Improvement and ≥2-Point Improvement in NAS and MRI-PDFF NASH Resolution at Week 24 Response and ALT Response 30% 80% *** 60% *** 60% *** 20% 52% 20% *** 14%

  16. Slide 16: Robust Liver Fat Reduction by MRI-PDFF

    WEEK 24 Pegozafermin Demonstrated Robust Liver Fat Reduction with High Responder Rates by MRI-PDFF 1 Mean Relative Reduction in Liver Fat vs Baseline Patients Achieving ≥30% and ≥50% Reduction in 2 at Week 24 Hepatic Fat Fraction Versus Baseline Placebo 30mg QW 44mg Q2W N=48 N=49 N=35 100% 0% -10% 8

  17. Slide 17: Improvements in ALT and AST

    WEEK 24 Pegozafermin Demonstrated Significant Improvements in Markers of Liver Injury/Inflammation (ALT and AST) Mean Relative Reduction in ALT vs Mean Relative Reduction in AST vs Baseline at Week 24 Baseline at Week 24 Placebo 30mg QW 44mg Q2W Placebo 30mg QW 44mg Q2W n=61 n=66 n=51 n=61 n=66 n=51

  18. Slide 18: Reductions in Non-Invasive Markers of Inflammation and Fibrosis

    WEEK 24 Pegozafermin Demonstrated Significant Reductions in Non-Invasive Markers (NITs) of Liver Inflammation and Fibrosis cT1 - Absolute Change from VCTE - Absolute Change from FAST - Percent Change from Baseline at Week 24 (ms) Baseline at Week 24 (kPa) Baseline at Week 24 0 0% 0.8 0.5 -6 -6% -20

  19. Slide 19: Improvements on Non-Invasive Markers for Fibrosis

    WEEK 24 Pegozafermin Demonstrated Significant Improvements on Non- Invasive Markers (NITs) for Fibrosis ELF - Absolute Change from FIB-4 - Absolute Change from PRO-C3 - Percent Change from Baseline at Week 24 (ms) Baseline at Week 24 (kPa) Baseline at Week 24 0.3 0.2 6% 0.2 0.1 5% 0.1 0.0 -5% -0.1 -

  20. Slide 20: Sustained Benefits Across Liver NITs at 48 Weeks

    WEEK 48 Pegozafermin Demonstrated Sustained Benefits Across Key Liver NITs and Metabolic Markers At 48 Weeks of Treatment BACKGROUND KEY RESULTS • After the Main Study (week 24), patients entered • Robust effects were observed at week 48 on liver a 24-week blinded Extension Phase for a total of fat

  21. Slide 21: ENLIVEN Patient Disposition and Analysis Sets

    ENLIVEN Patient Disposition and Analysis Sets DOSED Safety Analysis Set Ineligible per 3-panel read N=219 • Stage F1 (n=7) • Stage F4 (n=14) • Stage F2/F3 but NAS <4 (n=6) F2/F3, NAS≥4 N=192 Full Analysis Set (FAS) Placebo 15mg QW 30mg QW 44mg Q2W n=61 n=14 n=66 n=51 Extension Placebo 30mg QW Phase

  22. Slide 22: Maintained Liver Fat Reduction by MRI-PDFF

    WEEK 48 Pegozafermin Maintained Robust Liver Fat Reduction Measured by MRI-PDFF 1 Median Relative Reduction in Liver Fat vs Baseline at Week 48 Placebo 30mg QW 44mg Q2W N=25 N=39 N=28 0% -10% -11% -20% -30% -40% -50% * -47% -60% ** -60% -70% 84% of super-responders on PGZ 30 mg QW at week 24 maintai

  23. Slide 23: Sustained Improvements in ALT and AST over 48 Weeks

    WEEK 48 Pegozafermin Demonstrated Sustained Improvements in Markers of Liver Injury/Inflammation (ALT and AST) over 48 Weeks Mean Percent Change from Baseline ALT AST Baseline Week 12 Week 24 Week 48 Baseline Week 12 Week 24 Week 48 0% 0% -11% -4% -10% -10% -20% -20% -30% -30% ** *** -35% -36% -40%

  24. Slide 24: Reductions in NITs of Liver Inflammation and Fibrosis

    WEEK 48 Pegozafermin Demonstrated Significant Reductions in NITs of Liver Inflammation and Fibrosis FAST Pro-C3 VCTE (kPa) ELF Score 30mg 44mg 30mg 44mg 30mg 44mg 30mg 44mg Placebo QW Q2W Placebo QW Q2W Placebo QW Q2W Placebo QW Q2W n=33 n=48 n=40 n=33 n=48 n=40 n=42 n=66 n=51 n=42 n=66 n=51 0.0 10%

  25. Slide 25: Continued Benefit in Metabolic Endpoints

    WEEK 48 Pegozafermin Demonstrated Continued Benefit in Metabolic Endpoints HbA1c Triglycerides LDL-C Non-HDL-C 30mg 44mg 30mg 44mg 30mg 44mg 30mg 44mg Placebo QW Q2W Placebo QW Q2W Placebo QW Q2W Placebo QW Q2W n=14 n=23 n=16 n=32 n=48 n=38 n=32 n=48 n=38 n=32 n=48 n=38 0.0 0% 0% 0% -5% -2% -3% -0.2

  26. Slide 26: Sustained Week 48 Improvements Across Liver NITs

    WEEK 24 Long-term Treatment with Pegozafermin Results in Sustained WEEK 48 Improvements over a Wide Range of Liver NITs Placebo Placebo 30mg QW 30mg QW 44mg Q2W 44mg Q2W Week 24 Week 48 Week 24 Week 48 Week 24 Week 48 (n=42) (n=35) (n=66) (n=50) (n=51) (n=45) MRI-PDFF -6% -11% -56% -60% -60% -47% AL

  27. Slide 27: Independent Patient Confirmation of Treatment Effect

    WEEK 48 Independent Patient Confirmation of Pegozafermin Treatment Effect Placebo Patients Showed Robust Benefits Upon Crossing Over to Pegozafermin Change from Baseline Main Study Extension Phase Parameter Placebo 30mg QW n=19 n=19 MRI-PDFF -21% -63% ALT -2% -32% AST -2% -31% PRO-C3 +8% -17% FAST -

  28. Slide 28: Additive Benefits to GLP-1 Therapy in Patients with NASH

    GLP1 Pegozafermin Offered Additive Benefits to GLP-1 Therapy in Patients with NASH through Week 48 KEY RESULTS BACKGROUND • Results from 37 patients in ENLIVEN who were Pegozafermin on top of GLP-1 therapy showed the on GLP-1 therapy at baseline – 25 received following versus GLP-1 plus placebo at w

  29. Slide 29: Fibrosis Markers vs GLP-1 Placebo at Week 24

    WEEK 24 Greater Benefits on Fibrosis Markers Were Observed with Pegozafermin vs. GLP1 Placebo in Patients on Background GLP-1 Therapy at Week 24 ALT (%) VCTE (kPa) ELF Score Pro-C3 (%) 0.5 40% 0% 0.0 +0.3 +26% 0.3 -0.5 -0.4 -11% 20% -1.0 0.1 -25% -1.5 -0.1 0% -2.0 -0.3 -38% -2.1 -0.4 -50% -0.5 -20%

  30. Slide 30: Metabolic Markers vs GLP-1 Placebo at Week 24

    WEEK 24 Greater Benefits on Metabolic Markers Were Observed with Pegozafermin GLP1 vs. Placebo in Patients on Background GLP-1 Therapy at Week 24 HbA1c Triglycerides (%) MRI-PDFF (%) Adiponectin (%) 0 0% 40% 0% 0% 33% -0.1 -10% -20% 30% -0.1 -0.2 -28% -20% -40% 20% -0.3 -30% -60% 10% -54% -0.4 -29%

  31. Slide 31: Sustained Fibrosis Marker Benefits with GLP-1 at Week 48

    WEEK 48 Sustained Benefits on Fibrosis Markers Were Observed with Pegozafermin GLP1 vs. Placebo in Patients on Background GLP-1 Therapy at Week 48 ELF Score FAST (%) Pro-C3 (%) ALT (%) 0 0% 0% 0% 0 -5% -0.2 -20% -20% -15% -10% -9% -15% -40% -40% -0.4 * -43% -20% -44% -19% -0.5 -52% -60% -0.6 -60% -2

  32. Slide 32: Sustained Metabolic Benefits with GLP-1 at Week 48

    WEEK 48 Sustained Benefits on Metabolic Markers Were Observed with Pegozafermin GLP1 vs. Placebo in Patients on Background GLP-1 Therapy at Week 48 MRI-PDFF (%) Triglycerides (%) LDL-C (%) Placebo PGZ Pooled Placebo PGZ Pooled Placebo PGZ Pooled n=8 n=17 n=8 n=18 n=8 n=18 0% 0% 0% -5% -20% -10% -12%

  33. Slide 33: Promising Profile in Compensated NASH Cirrhosis (F4)

    F4 Pegozafermin Offers a Promising Profile in Patients with Compensated NASH Cirrhosis (F4) KEY RESULTS BACKGROUND • ENLIVEN enrolled 14 NASH Stage F4 patients of • 45% of pegozafermin-treated patients had fibrosis * which 12 patients had follow-up biopsies at improvement ≥1 stage without worsening

  34. Slide 34: Fibrosis Improvement in 45% of F4 Patients

    WEEK 24 Pegozafermin Achieved Fibrosis Improvement Without Worsening F4 of NASH in 45% of Patients with F4 Fibrosis at Baseline Fibrosis Improvement ≥1 Stage Without Worsening of NASH 50% 45% • Pegozafermin treatment led to fibrosis improvement ≥1 40% stage in 9/11 treated patients (82%) 30% • Pegoz

  35. Slide 35: Potential Best-in-Category Fibrosis Regression in F4

    Pegozafermin Has Demonstrated Preliminary Evidence for Potential Best-in-Category Fibrosis Regression in Patients with F4 Fibrosis* FGF21 FGF21 Peg-FGF21 FGF19 GLP-1 FXR ASK1 PGZ | 24 weeks EFX | 36 weeks Pegbelfermin | 48 weeks Aldafermin | 48 weeks Sema | 48 weeks Ocaliva | 78 weeks Selonsertib |

  36. Slide 36: NIT Results over Weeks in F4 Patients

    WEEK 24 NIT Results over 48 Weeks in F4 Patients From ENLIVEN WEEK 48 Demonstrated Consistent Benefit F4 PGZ Treated Patients (n=12) Parameter 24 weeks 48 weeks Liver Fibrosis and Inflammation ELF (units) -0.3 -0.5 FAST -46% -42% VCTE (kPa) -2.7 -1.1 Pro-C3 -5% -20% FIB-4 -11% -16% Liver Injury ALT

  37. Slide 37: Pegozafermin Was Well Tolerated

    Pegozafermin Was Well Tolerated Through 48 Weeks Drug-related TEAEs in ≥10% of patients during the Main Study Placebo 15mg QW 30mg QW 44mg Q2W Preferred Term (n=69) (n=21) (n=72) (n=57) Diarrhea 3% 24% 17% 9% Nausea 1% 14% 21% 18% Injection site erythema 3% 14% 14% 5% Injection site rash 1% 0 10% 4%

  38. Slide 38: Phase 3 ENLIGHTEN Studies in NASH Expected to Initiate in 1H24

    Phase 3 ENLIGHTEN Studies in NASH Expected to Initiate in 1H24 FDA and EMA Generally Aligned on Phase 3 Program ENLIGHTEN-Fibrosis: ENLIGHTEN-Cirrhosis: in F2-F3 NASH patients in Compensated F4 NASH patients Design/ Randomized, double-blind, placebo-controlled trial Randomized, double-blind, placebo

  39. Slide 39: Potential to Address a Large Commercial Opportunity

    Pegozafermin Has Potential to Address a Large Commercial Opportunity NASH represents a large patient population with significant health risks • NASH is estimated to impact ~30M patients by 2030 in the US with equivalent number in EU Significant market opportunity for pegozafermin • Pegozafermin posi

  40. Slide 40: NASH Treatment Paradigm and Pegozafermin Positioning

    NASH Treatment Paradigm and Pegozafermin Positioning FIBROSIS STAGING F1 F2 F3 F4 (Compensated) LOW Risk Staging based on: MEDIUM • Fibrosis Progression HIGH • Liver Events • CV Events VERY HIGH Improve Glycemic Control / Improve Dyslipidemia / Reduce Weight Resolve Steatohepatitis Primary Treatment

  41. Slide 41: Pegozafermin Offers a Highly Differentiated Profile

    Pegozafermin Offers a Highly Differentiated Profile Pegozafermin differentiates on key attributes for an effective NASH drug * 1 EFFICACY: Potential best-in-category fibrosis data ; robust metabolic data; benefits on top of T2DM/obesity drugs 2 SAFETY AND TOLERABILITY: Potential best-in-class (FGF21

  42. Slide 42: Opportunity in Severe Hypertriglyceridemia (SHTG)

    Opportunity in Severe Hypertriglyceridemia (SHTG)

  43. Slide 43: Important New Treatment Option for SHTG

    Pegozafermin Could Offer an Important New Treatment Option for SHTG Topline results expected in 2025 Large growing patient population with significant health risks; overlap with NASH patient population • Increasing TG levels increase risk of acute pancreatitis, cardiovascular disease and all-cause m

  44. Slide 44: Phase 2 SHTG Trial Design

    – Phase 2 SHTG Trial Design KEY INCLUSION CRITERIA 8 Weeks• TG ≥500mg/dL and ≤2,000mg/dL PLACEBO (n=18) • Background therapy: statins and/or prescription fish oil and/or fibrates OR none 9mg QW Pegozafermin (n=16) PRIMARY ENDPOINT 18mg QW Pegozafermin (n=17) • Primary endpoint: % Change in TGs from

  45. Slide 45: Significantly Reduces Triglycerides Across All Dose Groups

    Pegozafermin Significantly Reduces Triglycerides Across All Dose Groups Median % Change in Triglycerides from Baseline at Week 8 QW Q2W Placebo 9mg 18mg 27mg 36mg -10% -12% Q1; Q3: [-23.22; 7.88] -30% * -36% Q1; Q3: [-62.39; -10.92] -50% *** *** -56% -57% Q1; Q3: [-67.60; -39.85] Q1; Q3: [-64.73; -4

  46. Slide 46: Triglyceride Decrease on Top of Background Therapy

    Pegozafermin Shows Significant Decrease in Triglycerides on Top of Background Therapy Median % Change in Triglycerides from Baseline at Week 8 Not On Background Therapy On Background Therapy QW Q2W QW Q2W Placebo 9mg 18mg 27mg 36mg Placebo 9mg 18mg 27mg 36mg n=6 n=8 n=8 n=6 n=8 n=11 n=8 n=9 n=10 n=8

  47. Slide 47: Triglyceride Decrease at Different Threshold Levels

    Pegozafermin Shows Significant Decrease in Triglycerides at Different Threshold Levels TG Normalization TG Reduction ≥50% from baseline Responders (<500 mg/dL) (<150mg/dL, <200mg/dL) *** 60% 100% 80% 75% *** 80% 44% 80% 60% 40% * 60% 31% 40% 40% 29% 20% 20% 20% 6% <150 <200 0% mg/dL mg/dL 0% 0% 0% P

  48. Slide 48: Improvements in Non-HDL-C and Apo-B

    Pegozafermin Demonstrated Clinically Meaningful Improvements in Non-HDL-C and Apo-B – Key Marker of CV Risk Mean % Change from Baseline at Week 8 Mean % Change from Baseline at Week 8 Non-HDL-C Apo-B Q2W QW Q2W QW Placebo 9mg 18mg 27mg 36mg Placebo 9mg 18mg 27mg 36mg Baseline (mg/dL): 218 216 203 20

  49. Slide 49: Improvement in Liver Fat and Glycemic Control in SHTG

    Pegozafermin Demonstrated Significant Improvement on Key Co- morbidities in SHTG – Liver Fat and Glycemic Control Mean Relative Reduction in Liver Fat vs Absolute Change in HbA1c at Week 8 Baseline at Week 8 Patients with Baseline HbA1c ≥6.5% Placebo PGZ pooled Placebo 27mg QW n=6 n=17 n=6 n=9 0% 0

  50. Slide 50: Favorable Safety/Tolerability Profile in Phase 2 Study

    Pegozafermin Demonstrated Favorable Safety/Tolerability Profile in Phase 2 Study • Pooled pegozafermin treatment related Adverse Events (AEs) observed in ≥7.5% of patients were: – Nausea (10%), diarrhea (9%) and injection site reaction (9%) vs placebo (0%) – All Gastrointestinal (GI) AEs were Grade

  51. Slide 51: Phase 3 ENTRUST Trial Design

    Phase 3 ENTRUST Trial Design KEY INCLUSION CRITERIA • TG ≥500mg/dL and 52 WEEKS ≤2,000mg/dL • Stable background lipid Placebo QW (n=90) modifying therapy* PRIMARY ENDPOINT Pegozafermin 20mg QW (n=135) • Percent change from baseline in fasting TGs at Week 26 vs. Pegozafermin 30mg QW (n=135) placebo K

  52. Slide 52: SHTG Represents a Large Population with High Unmet Need

    SHTG Represents a Large Population with High Unmet Need Prevalence in US PREVALENCE Co-morbidity SHTG UP TO 4 MILLION population Fatty Liver Disease Up to 100% (NAFLD) DIAGNOSED ~2.8 MILLION Type 2 Up to 70% diabetes/Prediabetes Dyslipidemia Up to 65% UN-TREATED DRUG TREATED ~1.1 MILLION ~1.7 MILLIO

  53. Slide 53: Delivers on Key Attributes for Successful SHTG Therapy

    Pegozafermin Delivers on Key Attributes for Successful SHTG Therapy MINOR INFLUENCE MODEST INFLUENCE MAJOR INFLUENCE Hierarchy of Attributes for SHTG Therapy RoA/Dosing Clinical Outcomes Safety/Tolerability Metabolic Endpoints TG Endpoints • RoA and dosing were • Physicians noted that • Lesser impac

  54. Slide 54: Profile Supports Utilization Over Current Standard of Care

    Pegozafermin Profile Supports Utilization Over Current Standard of Care and Future Competitive Agents IN DEVELOPMENT APPROVED Prescription Fish Oils Pegozafermin APOC3 Fibrates Statins Potential Potential Vascepa Lovaza Triglyceride reduction ✔✔✔✔✔✔✔✔✔✔✔✔✔ Liver fat/Fibrosis Worsens liver fat ✔/✔✔/

  55. Slide 55: Corporate Highlights

    Corporate Highlights Potential Best-in-Class FGF21 in Two Phase 3 programs, each of which * represents a significant market opportunity Nonalcoholic Steatohepatitis (NASH) Program 1 • Strongest fibrosis data in category with favorable tolerability and dosing convenience • First FGF21 with positive 4

  56. Slide 56: Appendix

    Appendix

  57. Slide 57: Experienced Management Team Positions 89bio for Success

    Experienced Management Team Positions 89bio for Success Rohan Palekar Hank Mansbach, MD Ryan Martins Quoc Le-Nguyen CEO CMO CFO CTO & Head of Quality CEO, CCO experience 20+ years biopharma and CFO, Strategy/IR, 20+ years biopharma and R&D leadership in clinical finance, sell-side leadership in tech

  58. Slide 58: Pegozafermin Exhibits Highly Potent FGF Receptor Agonism

    Pegozafermin Exhibits Highly Potent FGF Receptor Agonism FGFR2 FGFR3 FGFR4 FGFR1 2000 3000 BIO89-100 BIO89-100 BIO89-100 BIO89-100 2600 5500 FGF21 FGF21 1800 FGF21 FGF21 2600 2200 4500 1600 2200 1400 1800 3500 1800 1200 1400 2500 1400 1000 1000 1500 800 1000 600 600 500 600 0.0001 0.1 100 0.0001 0.1

  59. Slide 59: ENLIVEN Used Objective Biopsy Reading Methodology

    ENLIVEN Used Objective Biopsy Reading Methodology Designed to Reduce Histology Scoring Biases and Variability ALL BIOPSIES SCORED INDEPENDENTLY • Pathologists underwent AND SEPARATELY protocol-specific harmonization training Pathologist Pathologist Pathologist before and during trial #1 #2 #3 • Path

  60. Slide 60: Learnings from the Obeticholic Acid NASH Phase Program

    Learnings from the Obeticholic Acid NASH Phase 3 Program: Comparison of Single Central Reader vs. 3-Panel Consensus Improvement of Fibrosis by ≥ 1 Stage without Worsening NASH Resolution of NASH with No Worsening of Liver Fibrosis OBSERVATIONS: • Placebo response for NASH resolution is >2 fold highe

  61. Slide 61: Pre-Specified ITT Analysis Confirms Robustness of Primary Results

    Pre-Specified ITT Analysis Confirms Robustness of Primary Efficacy Results ITT (missing data = non-responder); (n=192) at Week 24 30mg QW 44mg Q2W Fibrosis improvement without worsening of NASH Effect Size (placebo-adjusted) 15% 16% p-value 0.019 0.015 NASH resolution without worsening of fibrosis E

  62. Slide 62: Consistent Fibrosis Improvement Across Prespecified Subgroups

    Pegozafermin Showed Consistent and Significant Benefit in Achieving Fibrosis Improvement Across Prespecified Subgroups Pegozafermin 30mg QW Pegozafermin 44mg Q2W Proportion Achieving Fibrosis Improvement Proportion Achieving Fibrosis Improvement BL T2DM: Yes BL T2DM: Yes BL T2DM: No BL T2DM: No BL F

  63. Slide 63: Metabolic Data: Benefits Maintained Over Time

    Metabolic Data: Benefits Maintained Over Time Change From Baseline at Week 24 and Week 48 Placebo Placebo 30mg QW 30mg QW 44mg Q2W 44mg Q2W Week 24 Week 48 Week 24 Week 48 Week 24 Week 48 (n=42) (n=35) (n=66) (n=50) (n=51) (n=45) HbA1c -0.2 -0.5 -0.6 -0.7 -0.5 -0.4 Triglycerides -3% -5% -27% -21% -1

  64. Slide 64: Meaningful Reductions in HbA1c (ENLIVEN)

    Pegozafermin Demonstrated Meaningful Reductions in HbA1c (ENLIVEN) Change in HbA1c from Baseline at Week 24 Total Population Baseline HbA1c ≥6.5% Placebo 30mg QW 44mg Q2W Placebo 30mg QW 44mg Q2W n=61 n=66 n=51 n=31 n=32 n=25 0.0 0.0 0.0 0.0 -0.1 -0.1 -0.2 -0.2 -0.3 -0.2 -0.4 -0.3 -0.4 * -0.5 -0.3 *

  65. Slide 65: Meaningful Changes in Serum Lipids (ENLIVEN)

    Pegozafermin Demonstrated Meaningful Changes in Serum Lipids (ENLIVEN) Percent Change in Serum Lipids from Baseline at Week 24 Triglycerides Non-HDL Cholesterol HDL Cholesterol 0% 0% 0% 20% *** 14% -6% -10% 10% * -10% 6% -20% 0% -7% -7% -3% *** -27% -30% -10% -10% Placebo 30mg QW 44mg Q2W Placebo 30

  66. Slide 66: Data from Cohort Support Impact in F4 Patients

    Data from Cohort 7 Support Pegozafermin’s Impact in F4 Patients Histology data - Fibrosis improvement ≥ 1 stage without worsening of NASH ranged from 17% to 57% Parameter PGZ Treated Patients (n=6) Liver Fibrosis VCTE (kPa) -3.8 FAST (%) -78.5% Pro-C3 (%) -25.5% Liver Injury ALT (%) -50.7% AST (%) -

  67. Slide 67: Comparative Profile of FGF21 Analogs – Safety/Tolerability

    Comparative Profile of FGF21 Analogs in NASH – Safety/Tolerability Pegozafermin (PGZ) Efruxifermin (EFX) 30mg QW 44mg Q2W 28mg 50mg Tolerability and safety (key terms) Diarrhea 17% 9% 35% 33% Nausea 21% 18% 25% 33% Frequent bowel - - 20% - Increased appetite 13% 5% 18% 23% Injection site erythema 14

  68. Slide 68: Comparative Profile of FGF21 Analogs – Histology and Liver Markers

    Comparative Profile of FGF21 Analogs - Histology and Liver Markers Pegozafermin (PGZ) Efruxifermin (EFX) 30mg QW 44mg Q2W 28mg 50mg • GlycoPEGylated FGF21 (40 kDa) Structure (molecular weight) Fc-fusion FGF21 (92 kDa) • Structurally different from other monovalent analogs 1 Potency against FGF recep

  69. Slide 69: Over 60% of T2D Patients Prefer Every-Two-Week Injections

    Over 60% of T2D Patients Prefer or Strongly Prefer Every-Two-Week Injections Preference of Every-Two-Week Injections Over Weekly Injections 100% 26.7% • Every-two-week dosing provides opportunity 63% 75% Prefer or for physicians to optimize therapy to patient preference Strongly 36.7% Prefer 50% • C

89bio — Investor Presentation (December 2023) on 6ix